BiochemProbe — Life Science Research Reagents

LY2562175 free base · Synonyms: LY-2562175 · LY 2562175

LY2562175 is a potent and selective farnesoid X receptor agonist.

For research use only. Not for human or veterinary use.

Target FXR Autophagy
Research area Metabolic Disease
Purity >98% Stock Inquire

LY2562175 structure

CAS No.: 1103500-20-4

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
100 mg USD 650.00 BP-02141-100mg In stock Get quote
250 mg USD 1,280.00 BP-02141-250mg In stock Get quote
500 mg USD 1,980.00 BP-02141-500mg In stock Get quote
1 g USD 3,200.00 BP-02141-1g Inquire Get quote

Need another size or custom synthesis? Request a quote.

Description

LY2562175 is a potent and selective farnesoid X receptor (FXR) agonist. LY2562175 promotes transcriptional activation of human FXR in a cell-based cotransfection assay with EC50 of 193 nM.

Biological activity

In Vitro LY2562175 promotes transcriptional activation of human FXR in a cell-based co-transfection assay with an EC50 of 193 nM. LY2562175 promotes recruitment of a peptide from the nuclear receptor interaction domain of the coactivator SRC-1 with a relative EC50 of 121 nM and 93.5% efficacy as compare to GW4064. In Vivo LY2562175 causes a dose-dependent decrease in serum cholesterol and serum triglycerides. At a dose of 10 mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from control group. The ED50 for serum cholesterol is determined to be 2 and 3.4 mg/kg for serum triglycerides. Treatment of female ZDF rats with LY2562175 results in a dose dependent lowering of plasma triglycerides in the fasted and nonfasted states. When administered as a fixed dose combination with BRL49653, LY2562175 further lowers fasted and nonfasted plasma triglycerides. FPLC fractionation of the lipoproteins reveals that LY2562175 treatment results in a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model.

Identifiers

SMILES
CN1C=C(C(O)=O)C2=C1C=C(C=C2)N1CCC(CC1)OCC1=C(ON=C1C1=C(Cl)C=CC=C1Cl)C1CC1
InChIKey
RPVDFHPBGBMWID-UHFFFAOYSA-N

Specifications

MW (average)
540.4380
Formula
C28H27Cl2N3O4
CAS No.
1103500-20-4
Physical state
Solid
Color
White to light yellow
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMF: 20 mg/ml DMSO: 30 mg/ml DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml

References

[1]. Genin MJ, et al. Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1H-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia. J Med Chem. 2015 Dec 24;58(24):9768-72.

Same target

Search FXR

Same research area

Search Metabolic Disease

Recently viewed